JP2011195532A - Protein glycation inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a protein glycation inhibitor, a wrinkle-ameliorating agent and a darkening-ameliorating agent each exhibiting excellent protein glycation-inhibiting performances.SOLUTION: The protein glycation inhibitor, the wrinkle-ameliorating agent and the darkening-ameliorating agent each comprise a plant body or an extract thereof of Ficus erecta Thunb., Aster ageratoides Turcz. var. ageratoides, Aster microcephalus (Miq.) Franch. et Sav. var. ovatus (Franch. et Sav.) Soejima et Mot. Ito, Stauntonia hexaphylla (Thunb.) Decne., Quercus variabilis Blume, Pellionia minima Makino, Clerodendrum trichotomum Thunb. and Staphylea bumalda DC.

Description

  The present invention relates to a protein saccharification inhibitor that suppresses glycation of proteins such as collagen, and more specifically to a protein saccharification inhibitor containing a plant extract as an active ingredient.

  Glycation is a general term for a phenomenon (Maillard reaction) in which sugars are irreversibly and irreversibly bound to blood vessels and extracellular matrix (ECM) due to the influence of blood sugar concentration and the like. Recent studies have shown that glycation progresses with age, including arteriosclerosis and clouding of the lens, diabetes, various diseases associated with diabetes (arteriosclerosis, cataracts, impaired kidney function, etc.), Alzheimer's disease, etc. It is also known to cause various diseases.

  In addition, as human skin ages, protein saccharifies and deteriorates, so that the state of the skin decreases, and wrinkles, sagging, dullness, etc. are likely to occur. In particular, in recent years, it has become a problem that glycation of skin proteins is promoted by the influence of stress in social life.

  From such a background, various drugs having an action of suppressing protein glycation have been proposed (see Patent Documents 1 to 6). However, since further aging, worsening of stress and worsening of the living environment are expected in the future, further improvement in the ability to inhibit glycation of proteins has been desired.

JP 2007-131599 A JP 2006-28090 A JP 2000-309521 A Japanese Patent Laid-Open No. 2003-300894 JP 2004-217544 A JP 2004-217545 A

  Thus, suppression of protein glycation is involved in improving various symptoms caused by the above-mentioned diseases and aging, and a substance that suppresses protein glycation is also required in this respect. Among them, in recent years, from the viewpoint of safety, it is particularly required to be a component derived from natural products such as plants.

  An object of the present invention is to provide a protein saccharification inhibitor that has an excellent ability to suppress protein glycation, has no side effects even when used for a long period of time, and can be easily used, in response to the conventional situation as described above. And

  As a result of intensive studies in view of the present situation, the present inventors have found that a specific plant extract has an excellent protein glycation-inhibiting action, and have completed the present invention.

  The present invention is a protein saccharification inhibitor comprising one or more selected from plants of Inubiwa, white yomena, wildflower, mube, abemaki, salamander, sage and honeybee, or an extract thereof.

  Moreover, this invention is a wrinkle improving agent characterized by including the 1 type (s) or 2 or more types chosen from the plant body of Mube and Salamander, or its extract.

  Furthermore, this invention is a dullness improving agent characterized by including the 1 type (s) or 2 or more types chosen from the plant body or its extract of Shiroyomena, Shirokonaku, Mube, Salamander, and honeybee.

  The protein saccharification inhibitor of the present invention has excellent protein saccharification inhibiting ability and can be used for prevention, improvement, treatment and the like of various symptoms, diseases, and pathological conditions involving protein saccharification. In particular, it can be used for prevention and improvement of wrinkles and dullness due to suppression of protein saccharification, and can be used as a wrinkle improving agent and dullness improving agent. Moreover, since the component derived from a natural product is used, it is safe even if used internally or externally for humans or animals.

Hereinafter, the present invention will be described in detail.
The protein saccharification inhibitor of the present invention is composed of at least one of plants such as Inubiwa, Shiroyomena, Japanese cornflower, Mube, Abemaki, Salamander, Japanese cypress, and honeybee. The protein saccharification inhibitor of the present invention has excellent protein saccharification inhibiting ability. Therefore, the protein saccharification inhibitor of the present invention is suitable as a material for foods and drinks (for example, supplements and beverages), pharmaceuticals (for example, external preparations for skin, internal medicines), quasi drugs, or cosmetics.

  Inubiwa (scientific name: Ficus erecta Thunb.) Used in the present invention is a plant belonging to the mulberry family and is known to be effective for neuralgia and beriberi ("Okinawa folk remedies and herbs"). JP-A-2009-40753 is considered to have a fibroblast growth promoting action, WO07 / 94312 has a vitamin C transporter production-promoting action, and JP-A-2002-179581 has a hyaluronidase inhibitory action.

  Shiroyomena (scientific name: Aster ageratoides Turcz. Var. Ageratoides) used in the present invention is a plant belonging to the family Asteraceae. Shiroyomena is used to improve sag in Japanese Patent Laid-Open No. 2008-50346.

  Wildflower (Scientific name: Aster microcephalus (Miq.) Franch. Et Sav. Var. Ovatus (Franch. Et Sav.) Soejima et Mot. Ito) used in the present invention is a plant belonging to the family Asteraceae. Japanese cornflower is used for improving the sag in Japanese Patent Laid-Open No. 2008-50346.

Mube (Scientific name: Stauntonia hexaphylla (Thunb.) Decne.) Used in the present invention is a plant of the family Akebidae, and it is known that the components in the fruit skin and flesh have anthelmintic action against roundworms and worms. It is said that the immature one has a higher anthelmintic action than the overheated one. Seeds and leaves are also said to have anthelmintic action.
In the private sector, stems, roots and pericarp are used as a diuretic in the private sector (“Makino Wakahan Herb Encyclopedia”). In China, fruits and seeds are used for anthelmintics, and stems and roots are used for cardiotonic and diuretics. Roots are known to have analgesic and sedative effects (“World Useful Plant Encyclopedia”).

Abemaki (scientific name: Quercus variabilis Blume) used in the present invention is a plant of the beech family, and the fruit is used for healthy stomach, astringency, anti-diarrhea, pressure ulcer, pressure sore, etc. It is known to improve scabies (“Makino Kazuhan Herb Encyclopedia”).
In China, fruits and shellfish are known to improve healthy stomach, diarrhea and cough ("World Useful Plant Encyclopedia"). In JP-A-11-292784, it is used as a skin external preparation for preventing aging, and it is used as a whitening agent in WO 2006/072756.

  The salamander (scientific name: Pellionia minima Makino) used in the present invention is a nettle plant, and is used for sprains as a folk medicine in China ("worldly useful plant encyclopedia"). JP 2007-70336 is exemplified as a natural product that may be added to the hair-growing composition, and WO 2007/004390 is used for the treatment or prevention of cachexia in diseases such as diabetes, endocrine disease, blood system disease, malignant tumor, tuberculosis. Examples of natural products that may be added to pharmaceutical preparations and foods.

The peony (scientific name: Clerodendrum trichotomum Thunb.) Used in the present invention is a plant belonging to the family Oleaceae, and it has been reported that the foliage has antihypertensive and sedative effects.
The stems and leaves of geese are used for rheumatism, half body insufficiency, hypertension, product, etc., and the roots are used for diuresis, healthy stomach, antipyretic, etc. In Chinese medicine, branches and leaves are known to improve hypertension, migraine, malaria, diarrhea, epilepsy, etc. (“World Useful Plant Encyclopedia”). JP 2002-179581 discloses a skin aging inhibitor (skin aging inhibitor having an action of removing active oxygen) and JP 2000-178198 discloses a cell activator (aging prevention by fibroblast activation). Is used as an external preparation for skin having whitening, rough skin improvement, skin firmness and wrinkle improvement effects, and as an elastase inhibitor in JP 2002-179581 A.

  The honey beetle used in the present invention (scientific name: Staphylea bumalda DC.) Is a plant belonging to the honey beetle family, and is said to improve dry cough and blood sterilization of women after birth (“Chokuryaku Daiten Dictionary”).

  However, there has never been a report that the plant body or plant extract described above has a protein glycation-inhibiting action, and it has been found for the first time by the present inventors.

  In addition, the plant body of each plant used in the present invention or an extract thereof refers to various parts of each plant body (flower, flower ear, fruit skin, fruit, stem, leaf, branch, branch leaf, trunk, bark, rhizome, root). Skin, roots, seeds, whole grass, etc.) as they are or dried and pulverized into dry powders, or as they are or after drying and pulverizing and then extracted with a solvent.

  In the case of an extract, the extraction solvent used for extraction may be any solvent that is usually used for extraction, in particular alcohols such as methanol, ethanol or 1,3-butylene glycol, hydrous alcohols, acetone, ethyl acetate, etc. These organic solvents can be used alone or in combination. Of these, alcohols and hydrous alcohols are particularly preferred, and methanol, ethanol, 1,3-butylene glycol, hydrous ethanol or hydrous 1,3-butylene glycol are particularly preferred. . The solvent is preferably used at a temperature between room temperature and the boiling point of the solvent.

  There are no particular limitations on the extraction method, but usually it may be in the range of the boiling point of the solvent at room temperature to normal pressure. After extraction, the solution is filtered, ion exchanged, adsorbed, decolored and purified. , Paste, gel, and powder. In many cases, it can be used as it is, but if necessary, further purification treatment such as deodorization and decoloration may be added as long as the effect is not affected. An activated carbon column or the like may be used, and usual means generally applied depending on the extracted substance may be arbitrarily selected.

  As the extraction site of the plant body, the fruit for Inubiwa, the aerial part for Shiroyomena, the aerial part for cornflower, the fruit for Mubei, the fruit for Abemaki, the whole plant for Salamander, the leaf for Wedge, the honeybee For, branches are preferred, but extracts from other sites can also be used.

  The protein saccharification inhibitor of the present invention is preferably composed of one or more of each plant or extract thereof, but contains other various components as long as the effects of the present invention are not impaired. I can do it.

  The protein saccharification inhibitor of the present invention can be blended with a topical skin preparation and used for humans and animals, and can be blended with various foods and drinks, feed (such as pet food) and ingested. It can also be administered to humans and animals as a pharmaceutical formulation. At this time, it may be adjusted by arbitrarily drying, concentrating or diluting depending on the dosage form and form of the external preparation for skin and food and drink. In particular, the plant of the present invention or an extract thereof can be suitably used as a wrinkle improving agent or dullness improving agent based on protein saccharification inhibiting action.

  When mix | blending the protein saccharification inhibitor of this invention with a skin external preparation, the extract of each plant body is preferable, and the compounding quantity (dry mass) is generally 0.0001-10 mass% in the external preparation whole quantity.

  When the present invention is applied to an external preparation for skin, in addition to the above components, components that are usually used in external preparations for skin such as cosmetics and pharmaceuticals within the range that does not impair the effects of the present invention, if necessary, such as antioxidants Oils, UV protection agents, surfactants, thickeners, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.

  Furthermore, edetate disodium, edetate trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, preservatives such as methylparaben, ethylparaben, butylparaben, caffeine, tannin, Verapamil, tranexamic acid and its derivatives, licorice extract, grabrizine, hot water extract of karin fruit, various herbal medicines, tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, Whitening agents such as ascorbic acid glucoside, arbutin, and kojic acid, and sugars such as glucose, fructose, mannose, sucrose, and trehalose can also be appropriately blended.

  The external preparation for skin can be applied to cosmetics, quasi-drugs, etc., particularly preferably cosmetics applied to the outer skin, and the dosage form can also be applied to the skin. Any dosage form such as solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, ointment, lotion, gel, aerosol, etc. is applicable. Is done.

  The use form is also arbitrary, and for example, it can be used for facial cosmetics such as lotions, emulsions, creams and packs, makeup cosmetics such as foundations, lipsticks and eye shadows, aromatic cosmetics, bath preparations and the like.

  In addition, makeup cosmetics can be widely applied to foundations and the like, and toiletries such as body soaps and soaps. Furthermore, if it is a quasi-drug, it can be widely applied to various ointment forms. And the form which can take the protein saccharification inhibitor of this invention is not limited to these dosage forms and forms.

  When the protein saccharification inhibitor of the present invention is blended in foods and drinks, feeds, etc., the blending amount (dry mass) of the plant body or its extract is appropriately determined according to the type, purpose, form, usage method, etc. For example, in the case of tablets and capsules in the total amount of food and drink, 1 to 90% by mass is preferable, and in other foods and drinks, 0.001 to 50% by mass is preferable. It is preferable to prepare so that the daily intake of the plant or its extract per adult is about 1 to 1,000 mg. In particular, when used as a health food or drink, it is preferable to contain the active ingredient of the present invention in such an amount that a predetermined effect is sufficiently exhibited.

  As a form of food-drinks or feed, it can be arbitrarily shaped into, for example, granules, granules, pastes, gels, solids, or liquids. These include various known substances that are recognized to be contained in foods and drinks, such as binders, disintegrants, thickeners, dispersants, reabsorption accelerators, flavoring agents, buffers, and surfactants. Excipients such as solubilizers, preservatives, emulsifiers, tonicity agents, stabilizers and pH adjusters may be included as appropriate.

  When the protein saccharification inhibitor of the present invention is used as a pharmaceutical preparation, the preparation is appropriately used orally or parenterally (intravenous administration, intraperitoneal administration, etc.). The dosage form is also arbitrary, for example, oral solid preparations such as tablets, granules, powders and capsules, oral liquid preparations such as internal liquids and syrups, and parenteral liquid preparations such as injections. These forms can also be appropriately prepared by known methods. For these pharmaceutical preparations, commonly used binders, disintegrants, thickeners, dispersants, reabsorption accelerators, corrigents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonicity Excipients such as agents, stabilizers and pH adjusters may be used as appropriate.

  When the protein saccharification inhibitor of the present invention is used as an external preparation for skin, foods and drinks, feeds, pharmaceutical preparations, etc., it is used for treatment, prevention, improvement, etc. of various symptoms, diseases, and pathological conditions involving protein non-enzymatic saccharification. Useful. Specific application examples include, for example, diabetes that is a lifestyle-related disease, various diseases associated with diabetes (arteriosclerosis, cataract, decreased kidney function, etc.), Alzheimer's disease, malignant tumor, bone disease, neurodegenerative disease It is suitably used for the prevention and treatment of symptoms such as sagging / wrinkle of the skin, elasticity and reduced elasticity, and diseases. In addition, with the concept of physiological functions such as treatment, prevention, and improvement of the above symptoms, diseases, and pathological conditions, it should be applied to external preparations for skin, functional foods, foods for the sick, foods for specified health use, etc. Can do.

  The method for adding the protein saccharification inhibitor of the present invention to an external preparation for skin or food and drink may be added in advance or during production, and may be appropriately selected in consideration of workability. good.

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Unless otherwise specified, the amount is shown in mass%.
Initially, the preparation method of the plant extract used in the present Example, the test method regarding protein saccharification inhibitory effect, and its result are demonstrated.

1. Sample preparation All samples were grown in Kochi Prefecture and obtained from the Kochi Prefecture Makino Memorial Foundation.
The following samples were prepared and used as test samples.
(1) Inubiwa extract 9.14 g of dried Inubiwa fruit was immersed in 80 mL of methanol for 1 week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 1362 mg (yield: 14.9%) of Inubiwa methanol extract.
(2) Shiroyomena extract 8.73 g of Shiroyomena above-ground dried product was immersed in 80 mL of methanol for one week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 676 mg (yield: 7.7%) of a shiroyomena methanol extract.

(3) Sorghum extract 10.47 g of dried above ground sorghum was soaked in 80 mL of methanol for 1 week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with a filter paper to obtain 995 mg (yield: 9.5%) of konjac methanol extract.
(4) Mube Extract 6.92 g of dried Mube fruit was immersed in 80 mL of methanol for 1 week at room temperature. Next, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 3152 mg (yield: 45.6%) of Mbemethanol extract.

(5) Abemaki extract 7.66 g of dried Abemaki fruit was immersed in 80 mL of methanol for 1 week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 1075 mg (yield: 14.0%) of Abemak methanol extract.
(6) Salamander extract 6.39 g of dried salamander whole plant was immersed in 80 mL of methanol at room temperature for 1 week. Subsequently, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 453 mg (yield: 7.1%) of a salamander methanol extract.

(7) Wedge Extract 7.38 g of dried wagtail leaves were soaked in 80 mL of methanol for 1 week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with filter paper to obtain 909 mg (yield: 12.3%) of Kusagi methanol extract.
(8) Honey Bee Cryptus Extract 9.07 g of the dried honey beetle branch was immersed in 80 mL of methanol for 1 week at room temperature. Subsequently, the solvent was distilled off from the extract obtained by filtration with a filter paper to obtain 323 mg (yield: 3.6%) of a Mitsubatsugi methanol extract.

2. Protein glycation inhibitory test method and results 1. Using each plant extract obtained in step 1 as a test sample, the protein saccharification inhibitory effect was measured and evaluated by the following method.

1 / 6M glucose 6-phosphate disodium hydrate, 10 mg / mL human serum albumin and dimethyl sulfoxide (DMSO (Dimethyl sulfoxide)) prepared in a 96-well plate with phosphate buffered saline (PBS) The test substance solution (final concentration: 4 mg / mL) prepared in (1) was added and incubated at 37 ° C. for 11 days.
After the incubation, the production amount of CML (Ne- (carboxymethyl) lysine), which is one of the final glycation products, was measured by the ELISA method with a CircuitLex ™ CML / Ne- (carboxymethyl) lysine ELISA Kit (CycLex).
Table 1 shows the amount of CML in each sample solution when the amount of CML (carboxymethyllysine) in a control (control) to which no test substance solution was added was taken as 100. Here, CML (carboxymethyllysine) is one of advanced glycosylation end products (AGEs) which are end glycation products, and serves as a glycation marker.

As can be seen from Table 1, the plant extract of the present invention has an excellent protein saccharification inhibitory effect, and is useful as a protein saccharification inhibitor, a wrinkle improving agent based on a protein saccharification inhibiting action, and a dullness improving agent.
Therefore, by blending the protein saccharification inhibitor of the present invention, it is possible to provide a skin external preparation, an oral composition (for example, a functional agent, food and drink) having a protein saccharification inhibitory effect, a pharmaceutical preparation, etc. It is useful for the prevention, prevention, improvement, treatment, etc. of various symptoms, diseases and pathologies involving non-enzymatic saccharification.
Specific applications include diabetes, various diseases associated with diabetes (arteriosclerosis, cataracts, decreased kidney function, etc.), Alzheimer's disease, malignant tumors, bone diseases, neurodegenerative diseases, skin sagging / wrinkles, elasticity / elasticity Prevention, prevention, amelioration, and treatment of symptoms and diseases such as reduction. However, application is not limited to these examples.

  Below, the compounding example of the protein saccharification inhibitor by this invention of various dosage forms is demonstrated as a formulation example. Needless to say, the present invention is not limited by these formulation examples and is specified by the scope of claims.

[Formulation Example 1: Candy]
2000mg sugar
Minamata 1926mg
Protein glycation inhibitor: Inubiwa hydrous ethanol extract (dry mass) 20mg
Collagen peptide 10mg
Pearl barley extract (dry mass) 2mg
Lotus germ extract (dry mass) 2mg
Fragrance 40mg
(Total) 4000mg

[Formulation Example 2: Tablet]
Sucrose ester 70mg
Crystalline cellulose 74mg
Methylcellulose 36mg
Glycerin 25mg
Black bear extract 300mg
Protein saccharification inhibitor: Shiroyomena hot water extract (dry mass) 120mg
Collagen peptide 60mg
Pearl barley extract (dry mass) 10mg
N-acetylglucosamine 180mg
Hyaluronic acid 150mg
Vitamin E 30mg
Vitamin B6 20mg
Vitamin B2 10mg
α-Lipoic acid 20mg
Coenzyme Q10 40mg
Ceramide (konjac extract) 55mg
L-proline 300mg
(Total) 1500mg

[Formulation formulation example 3: soft capsule A]
Edible soybean oil 528mg
Protein saccharification inhibitor: Sorghum hydrous ethanol extract (dry mass) 90mg
Collagen peptide 45mg
Pearl extract (dry mass) 8mg
Lotus germ extract (dry mass) 16mg
Royal Jelly 70mg
Maca 60mg
GABA (γ-aminobutyric acid) 30mg
Beeswax 60mg
Gelatin 375mg
Glycerin 113mg
Glycerin fatty acid ester 105mg
(Total) 1500mg

[Formulation Example 4: Soft Capsule B]
Brown rice germ oil 650mg
Protein saccharification inhibitor: Mube hot water extract (dry mass) 300mg
Collagen peptide 255mg
Pearl barley extract (dry mass) 50mg
Resveratrol 5mg
Elastin 180mg
DNA 30mg
Folic acid 30mg
(Total) 1500mg

[Formulation Example 5: Granules]
Protein saccharification inhibitor: Abemaki hot water extract (dry mass) 140mg
Collagen peptide 70mg
Pearl barley extract (dry mass) 20mg
Lotus germ extract (dry mass) 40mg
Vitamin C 150mg
Soy isoflavone 270mg
Reduced lactose 360mg
Soybean oligosaccharide 36mg
Erythritol 36mg
Dextrin 30mg
Fragrance 24mg
Citric acid 24mg
(Total) 1200mg

[Composition Example 6: Drink (in 50 mL)]
Protein saccharification inhibitor: Salamander hydrous ethanol extract (dry mass) 10mg
Collagen peptide 5mg
Pearl barley extract (dry mass) 2mg
Reduced maltose starch syrup 28mg
Erythritol 8mg
Citric acid 2mg
Fragrance 1.3mg
N-acetylglucosamine 1mg
Hyaluronic acid 0.5mg
Vitamin E 0.3mg
α-Lipoic acid 0.2mg
Coenzyme Q10 1.2mg
Ceramide (konjac extract) 0.4mg
L-proline 2mg
Water residue

[Formulation Example 7: Ointment]
(Compounding ingredients) (mass%)
Protein saccharification inhibitor: Wedge water-containing ethanol extract (dry mass) 1.0
Stearyl alcohol 18.0
Owl 20.0
Polyoxyethylene (20) monooleate 0.25
Glycerin monostearate 0.3
Vaseline 40.0
Purified water residue

[Formulation formulation example 8: serum]
(Compounding ingredients) (mass%)
(Phase A)
95% ethyl alcohol 10.0
Polyoxyethylene (20) octyldodecanol 1.0
Pantothenyl ethyl ether 0.1
Protein saccharification inhibitor: Mitsubatsugi methanol extract (dry mass) 1.5
Methylparaben 0.15
(Phase B)
Potassium hydroxide 0.1
(Phase C)
Glycerin 5.0
Dipropylene glycol 10.0
Sodium bisulfite 0.03
Carboxyvinyl polymer 0.2
Purified water residue

[Composition example 9: Pack]
(Compounding ingredients) (mass%)
(Phase A)
Dipropylene glycol 5.0
Polyoxyethylene (60) hydrogenated castor oil 5.0
(Phase B)
Protein saccharification inhibitor: Inubiwa hydrous ethanol extract (dry mass) 0.01
Olive oil 5.0
Tocopherol acetate 0.2
Ethylparaben 0.2
Fragrance 0.2
(Phase C)
Sodium bisulfite 0.03
Polyvinyl alcohol (degree of saponification 90, degree of polymerization 2000) 13.0
Ethanol 7.0
Purified water residue

[Formulation formulation example 10: emulsion]
(Compounding ingredients) (mass%)
Microcrystalline wax 1.0
Beeswax 2.0
Lanolin 20.0
Liquid paraffin 10.0
Squalane 5.0
Sorbitan sesquioleate ester 4.0
Polyoxyethylene (20) sorbitan monooleate 1.0
Propylene glycol 7.0
Protein saccharification inhibitor: Shiroyomena methanol extract (dry mass) 10.0
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount of purified water

[Formulation Example 11: Cream]
(Compounding ingredients) (mass%)
Solid paraffin 5.0
Beeswax 10.0
Vaseline 15.0
Glycerin monostearate ester 2.0
Polyoxyethylene (20) sorbitan monolaurate 3.0
Soap powder 0.1
Borax 0.2
Protein saccharification inhibitor: Sorghum hot water extract (dry mass) 0.05
Sodium bisulfite 0.03
Ethylparaben 0.3
Perfume Appropriate amount of purified water

[Composition Example 12: Drink (in 50 mL)]
Protein saccharification inhibitor: Inubiwa hot water extract (dry mass) 5mg
Protein saccharification inhibitor: Shiroyomena hydrous ethanol extract (dry mass) 5mg
Collagen peptide 5mg
Pearl barley extract (dry mass) 2mg
Reduced maltose starch syrup 28mg
Erythritol 8mg
Citric acid 2mg
Fragrance 1.3mg
Hyaluronic acid 0.5mg
Vitamin E 0.3mg
Coenzyme Q10 1.2mg
Ceramide (konjac extract) 0.4mg
L-proline 2mg
Water residue

[Formulation Example 13: Tablet]
Sucrose ester 70mg
Crystalline cellulose 74mg
Methylcellulose 36mg
Glycerin 25mg
Black bear extract 300mg
Protein saccharification inhibitor: Shiroyomena hot water extract (dry mass) 40mg
Protein saccharification inhibitor: Salamander hot water extract (dry mass) 50mg
Collagen peptide 60mg
N-acetylglucosamine 180mg
Hyaluronic acid 150mg
α-Lipoic acid 20mg
Ceramide (konjac extract) 55mg
(Total) 1060mg

[Formulation Example 14: Soft capsule C]
Edible soybean oil 528mg
Protein glycation inhibitor: Inuviwa hot water extract (dry mass) 50mg
Protein saccharification inhibitor: Abemaki hydrous ethanol extract (dry mass) 80mg
Collagen peptide 43mg
Lotus germ extract (dry mass) 16mg
Royal Jelly 70mg
Maca 60mg
Beeswax 60mg
Gelatin 375mg
Glycerin 113mg
Glycerin fatty acid ester 105mg
(Total) 1500mg

Claims (3)

  A protein saccharification inhibitor comprising one or more selected from plants of Inubiwa, Shiroyomena, Sorghum, Mube, Abemaki, Salamander, Kusagi and Honeybee, or an extract thereof.   The wrinkle improving agent characterized by including the 1 type (s) or 2 or more types chosen from the plant body of Mube and Salamander, or its extract.   The dullness improving agent characterized by including the 1 type, or 2 or more types chosen from the plant body or its extract of Shiroyomena, Nokonjiku, Mube, Salamander, and Bee.